ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Disabling COMPASS Promoter Licensing Shifts HDAC-Inhibited Gastric Cancer Toward Sustained Transcriptional Suppression During Recovery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Histone deacetylase inhibitors (HDACi) broadly increase chromatin acetylation but have limited and variable activity in solid tumors. To define the epigenetic buffering axis that sustains promoter output during HDAC inhibition in gastric cancer. We integrated pharmacologic profiling across a molecularly diverse gastric cancer panel with an epigenetic-focused pooled CRISPR-Cas9 screening library, domain-resolved genetic perturbation, structure-guided WIN-pocket targeting, CCK8 time-course proliferation assays, and pulse-washout clonogenic recovery assays. Chromatin and transcriptional consequences were interrogated by assessing COMPASS integrity and chromatin association, promoter-proximal H3K4me3 dynamics, data-derived ATAC-seq accessibility, and transcriptional output. WDR5 abundance and baseline H3K4me3 levels were associated with sensitivity to combined HDAC and WDR5 WIN-pocket inhibition. Multiple orthogonal approaches identified the WDR5 WIN pocket as a key interface supporting chromatin-associated COMPASS and promoter-proximal H3K4me3 under the tested conditions. WIN-pocket disruption reduced chromatin recovery of COMPASS-associated components and attenuated H3K4me3 at selected growth-linked promoters. This produced a state with elevated H3K27 acetylation, attenuated H3K4me3, and reduced transcriptional output; data-derived ATAC-enriched regions retained a centered accessibility signal, although the mean peak amplitude was lowest in the combination. HDAC inhibitor response is conditioned by promoter licensing via the WDR5-COMPASS H3K4 methylation axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.